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ABSTRACT
Objective To compare reasons for discontinuation and 
drug retention rates per reason among anticytokine 
therapies, infl iximab, etanercept and tocilizumab, and the 
risk of discontinuation of biological agents due to adverse 
events (AE) in patients with rheumatoid arthritis (RA).
Method This prospective cohort study included Japanese 
RA patients who started infl iximab (n=412, 636.0 patient-
years (PY)), etanercept (n=442, 765.3 PY), or tocilizumab 
(n=168, 206.5 PY) as the fi rst biological therapy after 
their enrolment in the Registry of Japanese Rheumatoid 
Arthritis Patients for Long-term Safety (REAL) database. 
Drug retention rates were calculated using the Kaplan–
Meier method. To compare risks of drug discontinuation 
due to AE for patients treated with these biological 
agents, the Cox proportional hazard model was applied.
Results The authors found signifi cant differences among 
the three therapeutic groups in demography, clinical 
status, comorbidities and usage of concomitant drugs. 
Development of AE was the most frequent reason for 
discontinuation of biological agents in the etanercept and 
tocilizumab groups, and the second most frequent reason 
in the infl iximab group. Discontinuation due to good control 
was observed most frequently in the infl iximab group. 
Compared with etanercept, the use of infl iximab (HR 1.69; 
95% CI 1.14 to 2.51) and tocilizumab (HR 1.98; 95% CI 
1.04 to 3.76) was signifi cantly associated with a higher 
risk of discontinuation of biological agents due to AE.
Conclusions Reasons for discontinuation are 
signifi cantly different among biological agents. The use 
of infl iximab and tocilizumab was signifi cantly associated 
with treatment discontinuation due to AE compared with 
etanercept.
Biological disease-modifying antirheumatic drugs 
(biological agents) are a standard treatment for 
rheumatoid arthritis (RA).1 2 A number of clinical 
trials have demonstrated that biological agents 
signifi cantly improve signs and symptoms of RA 
patients with both early and established disease, 
and that remission of RA can be achieved with 
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biological agents not only in early RA patients, but 
also in established RA patients who have shown 
inadequate responses to conventional non-bio-
logical disease-modifying antirheumatic drugs 
(DMARD).
In Japan, six biological agents have been approved 
for the treatment of RA, infl iximab in 2002, etaner-
cept in 2005, tocilizumab and adalimumab in 2008, 
abatacept in 2010 and golimumab in 2011. These 
drugs are widely used in clinical practice accord-
ing to treatment guidelines for biological agents by 
the Japan College of Rheumatology3 4 and Japanese 
drug package inserts. Postmarketing surveillance 
and some clinical studies have shown short-term 
effectiveness and safety of these biological agents 
for Japanese RA patients.5–8 The European League 
Against Rheumatism recommendations for the 
management of RA state that a tumour necrosis 
factor (TNF) antagonist should be administered as 
the fi rst biological DMARD for patients who fail 
to respond to non-biological DMARD, including 
methotrexate,9 whereas Japanese guidelines do not 
clearly specify the precedence of biological agents.
Some RA patients treated with biological agents 
are compelled to stop the administration of these 
drugs because of lack of effi cacy (LOE), adverse 
events (AE), or fi nancial reasons. In addition, some 
RA patients discontinue biological agents in the 
hope of a biological-free remission or biological-
free low disease activity status.10–12 In general, 
drugs with high retention rates have a good balance 
between long-term effectiveness and tolerability, 
refl ecting the satisfaction of patients and doctors 
with the treatment. Because treatment for RA con-
tinues for many years or is life-long in the major-
ity of patients, the examination of long-term drug 
retention rates using a prospective cohort study is 
important for the evaluation of biological agents.
To establish better treatment strategies for RA, 
it is important to identify reasons and risk factors 
causing the discontinuation of a drug, especially for 
biological agents. Several studies have shown that 
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a frequent reason for the discontinuation of biological agents is 
the development of AE.5–7 13–16 Mid to long-term tolerability of 
TNF inhibitors6 13 14 16–24 and tocilizumab7 15 25 has been reported, 
and some studies have directly compared drug retention rates 
among TNF inhibitors or between TNF inhibitors and other 
biological agents.14 16 17 25–27 To summarise, infl iximab had the 
lowest overall retention rate among infl iximab, etanercept and 
adalimumab14 16 17 and among infl iximab, etanercept and anakin-
ra.26 A recent report from the CORRONA registry demonstrated 
the highest retention rate of infl iximab compared with etaner-
cept and adalimumab.27 However, drug retention rates have not 
been compared between TNF inhibitors and the interleukin-6 
receptor inhibitor, tocilizumab, in the real world. In addition, 
the risk factors causing drug discontinuation due to AE for 
patients given these biological agents have not been thoroughly 
evaluated.
The purpose of this study was to compare drug retention 
rates and reasons for discontinuation of infl iximab, etanercept 
and tocilizumab among Japanese RA patients, and to investigate 
the association of the use of these biological agents and other 
clinical characteristics with drug discontinuation due to AE.
PATIENTS AND METHODS
Database
The Registry of Japanese Rheumatoid Arthritis Patients for Long-
term Safety (REAL) is an ongoing prospective cohort established 
to investigate the long-term safety of biological agents in RA 
patients. Twenty-seven institutions participate, including 16 uni-
versity hospitals and 11 referring hospitals. Details of REAL have 
previously been described.28 29 Briefl y, the criteria for enrolment 
in REAL include patients meeting the 1987 American College of 
Rheumatology criteria for RA, written informed consent, and 
starting or switching treatment with biological agents or start-
ing, adding or switching non-biological DMARD at the time of 
enrolment in the study. Enrolment in the REAL database was 
started in June 2005 and closed in January 2012. To facilitate 
enrolment to the REAL registry, participating physicians were 
asked to enrol their patients already registered in postmarket-
ing surveillance programmes previously implemented by phar-
maceutical companies for biological agents.5 8 In addition, our 
investigators were also encouraged to enrol as many patients as 
possible who fulfi lled the inclusion criteria.29
Data were retrieved from the REAL database on 4 April 2011 
for this study. The REAL study was approved by the ethics com-
mittees of the Tokyo Medical and Dental University Hospital 
and other participating institutions.
Data collection
Each patient’s recorded baseline data included demography, disease 
activity, physical disability, comorbidities, treatments and labora-
tory data at the beginning of the observation period. A follow-up 
form was submitted by the site investigators every 6 months to 
the REAL data centre at the Department of Pharmacovigilance of 
Tokyo Medical and Dental University to report the occurrence 
of serious AE, current RA disease activity, treatments and clini-
cal laboratory data.28 29 We collected the Steinbrocker class30 as 
the baseline measurement for each patient’s physical disability, 
instead of the health assessment questionnaire disability index.31 
The investigators in each hospital confi rmed the accuracy of their 
data submitted to the REAL data centre. The centre examined all 
the data sent by site investigators and sent queries if necessary to 
verify the accuracy of the data.
Patients
By April 2011, 2067 RA patients were registered in REAL, of 
these 1044 patients started treatment with infl iximab, etanercept 
or tocilizumab at the time of enrolment or after enrolment in 
REAL. Four patients were excluded from this study because the 
reason for discontinuation of the initial biological agents was not 
identifi ed. Eighteen patients who were enrolled in another clini-
cal study requiring the discontinuation of infl iximab were also 
excluded. We did not include patients who used adalimumab, 
abatacept or golimumab as the fi rst biological agent in REAL 
because we did not have suffi cient numbers of patients on adali-
mumab in the database (n=98) compared with infl iximab and 
etanercept and had no patients given abatacept or golimumab in 
the database at the time our data were compiled. Our analysis 
included 412 patients who started infl iximab, 442 patients who 
started etanercept and 168 patients who started tocilizumab.
Follow-up
For patients who initiated biological agents (infl iximab, etan-
ercept, or tocilizumab) at enrolment in REAL, the start date 
Table 1 Characteristics of RA patients treated with infl iximab, etanercept or tocilizumab at the start of the observation period
Infl iximab group Etanercept group Tocilizumab group
p Value (n=412) (n=442) (n=168)
Age, years 53.6±13.5 58.5±13.0 59.8±13.4 <0.001
Female, % 85.9 78.1 80.4 0.011
Disease duration, years 7.9±7.8 10.3±8.9 10.3±9.6 <0.001
Steinbrocker’s class (3 or 4), % 24.8 31.2 27.4 0.108
Steinbrocker’s stage (III or IV), % 43.9 57.0 46.4 <0.001
DAS28 (3/CRP) 4.5±1.2 (n=411) 4.5±1.3 (n=440) 5.1±3.4 (n=167) 0.056
Use of ≥3 previous non-biological DMARD, % 41.0 54.5 31.5 <0.001
Biological-–naive, % 96.4 83.9 46.4 <0.001
Methotrexate use, % 99.3 44.6 44.0 <0.001
Methotrexate dose, mg/week 8.0±2.1 7.0±2.0 8.2±2.9 <0.001
Use of immunosuppressive drugs, except for methotrexate, % 1.9 5.7 14.9 <0.001
Oral corticosteroid use, % 68.9 73.1 60.1 0.008
Prednisolone-equivalent dose of corticosteroids (mg/day) 5.4±2.6 6.1±3.3 4.9±2.2 <0.001
Chronic pulmonary disease, % 22.6 36.7 40.5 <0.001
Diabetes mellitus, % 8.5 14.9 12.5 0.015
CRP, C-reactive protein; DAS28, disease activity score including 28-joint count; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis
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of the observation period was the date these agents were fi rst 
administered. For patients who started non-biological DMARD 
at the time of entry in REAL and who later started treatment 
with biological agents, the start of the observation period was 
the date of the fi rst administration of biological agents in REAL. 
Observation was stopped either at 2.5 years after the start of 
the observation period, on the date of death of a patient, loss 
to follow up, enrolment in clinical trials, or when therapy was 
stopped with the fi rst biological agent in REAL for more than 
90 days, or on 4 April 2011, whichever came fi rst. The period 
following switching to a second biological agent was excluded 
from this study. We defi ned termination of treatment with bio-
logical agents as stopping treatment with the agent for more 
than 90 days. The date of the last administration of each biologi-
cal DMARD was retrieved from medical records and reported 
by the site investigators. Reasons for drug discontinuation were 
obtained from case report forms of REAL supplemented by 
medical records, if necessary, and classifi ed into AE, good con-
trol, LOE or miscellaneous. We did not discriminate between a 
primary and secondary LOE. Note that we collected only seri-
ous AE in REAL, but also collected AE in this study if it was the 
main reason for the discontinuation of a biological agent. When 
a patient had two or more reasons for drug discontinuation, 
site investigators assigned precedence and we used the primary 
reason contributing to drug discontinuation for that patient.
Statistical analysis
The primary outcome of this study was the investigation of 
the association of the use of infl iximab, etanercept and tocili-
zumab with drug discontinuation due to AE. We also sought 
to identify other risk factors for drug discontinuation due to 
AE. Drug retention rates were calculated by the Kaplan–Meier 
method and compared using the log-rank test among groups. 
For univariate analysis, the χ2 test was used for comparison 
of categorical variables and the Kruskal–Wallis test was used 
for continuous variables among the three agents. For multivari-
ate analysis, the Cox regression hazard model with the forced 
entry method was employed to compare risks for drug discon-
tinuation due to AE. The validity of the proportional hazards 
assumption was confi rmed by the log-minus-log survival func-
tion. We followed the STROBE statement32 for clear reporting 
except for ‘the number and reasons for non-participation’ in 
this study.
These statistical analyses were conducted using SPSS (version 
16.0Illinois, ). All p values were two-tailed and p<0.05 was con-
sidered statistically signifi cant.
RESULTS
Baseline characteristics of the patients
This analysis included 412 patients in the infl iximab group 
(636.0 patient-years (PY)), 442 in the etanercept group (765.3 
PY) and 168 in the tocilizumab group (206.5 PY). Table 1 shows 
the baseline characteristics of the groups. There were signifi -
cant differences in age, gender, disease duration and clinical 
status of the patients. The etanercept and tocilizumab groups 
had longer disease duration (p<0.001) and higher percentages 
of comorbidities than the infl iximab group (p<0.001 for chronic 
pulmonary disease, p=0.011 for diabetes mellitus). The rates 
of biological-naive patients (96.4% for the infl iximab group, 
83.9% for the etanercept group and 46.4% for the tocilizumab 
group) (p<0.001) and of the use of three or more non-biological 
DMARD (p<0.001) in the tocilizumab group were the lowest 
among the three groups. The rate of the use (p=0.007) and dose 
(p<0.001) of oral corticosteroids of the etanercept group were 
higher than those for the other two groups. Disease activity did 
not differ signifi cantly among the groups.
Occurrence of treatment termination
The median IQR of the observation period for each group was 
1.50 (0.74–2.50) years for the infl iximab group, 2.1 (0.98–2.50) 
years for the etanercept group and 1.0 (0.5–2.0) years for the 
tocilizumab group. The number of patients who discontinued 
biological agents for any reason during the observation period 
was 157 (38.1%) for the infl iximab group, 130 (29.4%) for the 
etanercept group and 51 (30.4%) for the tocilizumab group 
(p=0.019 by χ2). Table 2 shows the reasons for drug discontinu-
ation for each group. A signifi cant difference among the three 
groups (p=0.026 by χ2) was seen in the proportions of reasons 
for discontinuation, and the adjusted residuals indicated that sig-
nifi cantly higher percentages of patients in the infl iximab group 
stopped treatment due to good disease control compared with 
the other two groups (p<0.05). The most frequently reported 
Table 2 Reasons for drug discontinuation in RA patients treated with infl iximab, etanercept or tocilizumab*
Reason for discontinuation Infl iximab (n=157)† Etanercept (n=130)† Tocilizumab (n=51)†
Adverse events 57 Cases (36.3%) 57 Cases (43.8%) 23 Cases (45.1%)
 Infection 20 Cases (12.7%) 22 Cases (16.9%)  8 Cases (15.7%)
 Pulmonary diseases except infection‡  7 Cases (4.5%)  7 Cases (4%)  3 Cases (5.9%)
 Infusion reaction  6 Cases (3.8%) NA  0 Case (0%)
 Allergy except infusion reaction  7 Cases (4.5%) 12 Cases (9.2%)  6 Cases (11.8%)
 Malignancy  6 Cases (3.8%)  3 Cases (2.3%)  1 Case (2%)
 Cardiovascular system disease  2 Cases (1.3%)  2 Cases (1.5%)  2 Cases (3.9%)
 Others  9 Cases (5.7%) 11 Cases (8.5%)  3 Cases (5.9%)
Lack of effi cacy 68 Cases (43.3%) 47 Cases (36.2%) 23 Cases (45.1%)
Good control 21 Cases (13.4%)  7 Cases (5.4%)  2 Cases (3.9%)
Miscellaneous§ 11 Cases (7.0%) 19 Cases (14.6%) §  3 Cases (5.9%)
The χ2 test was applied to assess differences in the proportion of causes for discontinuation (ie, adverse event, lack of effi cacy, good control and miscellaneous), and the adjusted 
residuals were calculated. A signifi cant difference among the three groups (p=0.026) was observed. The adjusted residuals indicated that signifi cantly higher percentages of patients 
in the infl iximab group stopped the treatment due to good disease control compared with the other two groups (p<0.05).
*Values are the number (percentage) of patients who discontinued use because of each reason.
†Number of patients who discontinued their fi rst biological DMARD for any reason.
‡Pulmonary diseases except for infection included interstitial pneumonia (three cases for infl iximab, fi ve for etanercept, two for tocilizumab) and other pulmonary diseases (four for 
infl iximab, two for etanercept, one for tocilizumab).
§Miscellaneous reasons for drug discontinuation include patients’ preference, fi nancial reasons, and pregnancy.
DMARD, disease-modifying antirheumatic drugs; RA, rheumatoid arthritis.
NA, not applicable
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reason for discontinuation was LOE in the infl iximab group, 
development of AE in the etanercept group and both in the 
tocilizumab group (table 2).
The retention rates of biological agents
Because the distribution of reasons for drug discontinuation was 
signifi cantly different among these biological agents (table 2), we 
investigated drug retention rates per reason for discontinuation. 
Kaplan–Meier curves for time to discontinuation for each agent 
due to AE and LOE are shown in fi gure 1A,B, respectively. No 
signifi cant differences existed among the three drugs for treat-
ment discontinuation due to AE. The discontinuation rate due to 
LOE was signifi cantly lower for etanercept compared with that 
of infl iximab (p=0.004, log-rank test) and tocilizumab (p=0.041) 
(fi gure 1B), and the discontinuation rate for infl iximab due to 
good control was signifi cantly higher than that for etanercept 
(p=0.001, log-rank test) (fi gure 1C). We combined withdrawals 
due to AE and LOE to assess treatment failure; etanercept had 
a signifi cantly lower discontinuation rate due to treatment fail-
ure compared with the other two agents (p=0.009 vs infl iximab, 
p=0.020 vs tocilizumab, log-rank test) (fi gure 1D). To evaluate 
the possible effects of previous treatment with biological agents 
on drug discontinuation due to AE and LOE, we compared the 
retention rates per reason except for good control in the etan-
ercept and tocilizumab groups between biological-naive and 
non-naive patients (see supplementary fi gures, available online 
only). In both groups, there was no signifi cant difference in drug 
retention rates between biological-naive and non-naive patients. 
However, we found a numerically higher discontinuation rate of 
biological agent non-naive patients due to LOE in the tocilizumab 
group (see supplementary fi gure S3, available online only).
Multivariate analysis of the risk for discontinuation of 
biological agents due to AE
We compared patients who discontinued treatment with biolog-
ical agents due to AE and remaining patients using a univariate 
analysis (see supplementary table S1, available online only) and 
used the same variables for the multivariate analysis of table 3. 
Although we found no signifi cant difference in the use of infl ix-
imab and tocilizumab in the univariate analysis (table S1, avail-
able online only), the Cox regression hazard model revealed that 
the adjusted risk for discontinuation due to AE was signifi cantly 
higher in patients using infl iximab (HR 1.69; 95% CI 1.14 to 
2.51) and tocilizumab (HR 1.98; 95% CI 1.04 to 3.76) compared 
with etanercept (table 3). Among the other variables, the risk 
of discontinuation due to AE was also signifi cantly higher in 
patients with increasing age by decade (HR 1.64; 95% CI 1.38 to 
1.97) and with the previous use of three or more non-biological 
DMARD (HR 1.86; 95% CI 1.30 to 2.67).
DISCUSSION
To our knowledge, this is the fi rst report comparing drug reten-
tion rates among TNF inhibitors and tocilizumab and identify-
ing risk factors causing drug discontinuation due to AE. The 
major fi ndings of this study are: (1) the reasons for discontinu-
ation were signifi cantly different among the three biological 
agents studied; (2) the risk of discontinuation due to AE was 
signifi cantly higher in patients using infl iximab and tocilizumab 
compared with etanercept; and (3) other signifi cant risk factors 
for the discontinuation due to AE were increasing age and the 
previous use of three or more non-biological DMARD.
There are some reports describing drug retention rates and 
reasons for drug discontinuations in patients treated with TNF 
Figure 1 Kaplan-Meier curves for time to discontinuation for each biological agent (etanercept (ETN); infl iximab (IFX); tocilizumab (TCZ)). 
Withdrawal for adverse events (A), lack of effi cacy (B), good control (C), and adverse events and lack of effi cacy (D) are presented separately. Drug 
retention rates are compared using the long-rank test among groups. The y axis shows the cumulative retention rates.
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inhibitors.14 16–18 20 22 24 26 27 33–35 Among patients stopping treat-
ment with TNF inhibitors due to any reason, approximately 
half of those discontinued due to AE, and the proportions of 
patients who discontinued the agents due to AE or LOE were 
similar in each group in the Swiss14 and the French16 registries. 
In this study, AE and LOE were the two major reported reasons 
for discontinuation, with similar percentages also for all three 
groups, but the discontinuation rate due to good control in the 
infl iximab group was signifi cantly higher than those in the other 
two groups. Several studies have shown successful discontinu-
ation of treatment with infl iximab10 36–40 and tocilizumab41
without fl are of RA, but the reported percentage of patients 
who could discontinue infl iximab was higher compared with 
tocilizumab. In contrast, there is no evidence of the successful 
discontinuation of treatment for etanercept to date. Therefore, 
our results might be infl uenced by physicians’ expectations for 
successful discontinuation of biological agents based on previ-
ous reports.
We observed a signifi cantly lower discontinuation rate due 
to LOE in the etanercept group compared with infl iximab and 
tocilizumab (fi gure.1B), which can be explained by the follow-
ing reasons. First, treatment with infl iximab induces the forma-
tion of human antichimeric antibody in some patients, which 
may lead to LOE or adverse drug reactions.42 43 The prevalence 
of antidrug antibodies in RA patients who were treated with 
infl iximab is much higher compared with etanercept44 45 and 
tocilizumab.15 46 Second, the tocilizumab group had a signifi -
cantly lower percentage of biological-naive patients, which may 
be associated with a less favourable response to treatment.47 48
In the tocilizumab group, we confi rmed that the discontinuation 
rate due to LOE was numerically lower in the biological-naive 
patients compared with biological agent non-naive patients (see 
supplementary fi gure S3, available online only).
In this study, we limited our multivariate analyses to the risk 
factors associated with discontinuation due to AE. Some previ-
ous studies identifi ed risk factors for overall discontinuation in 
patients treated with TNF inhibitors.6 17 26 Because treatments 
with biological agents are discontinued for various reasons, as 
shown in table 1, we postulated that it would not be appropriate 
to build a multivariate model for overall discontinuation from a 
medical point of view. In REAL, we did not collect measures of 
patients’ disease activity, such as the disease activity score in 28 
joints (DAS28), when patients stopped treatment with biological 
agents, and we could not defi ne discontinuation due to LOE by 
using objective criteria. Therefore, we opted not to analyse risk 
factors for discontinuation due to LOE. The number of patients 
who discontinued the agents due to good control was too small 
to analyse associated factors using multivariate analysis.
Increasing age was also identifi ed as a risk factor associated 
with the discontinuation of biological agents due to AE, data 
supported by a previous report.16 In all three groups, infections 
were most frequent among AE leading to drug discontinua-
tion (table 2). It is plausible that increasing age contributes to 
discontinuation because of an increasing risk of RA patients 
for infection29 49 with age. Higher numbers of previous non-
biological DMARD use suggests cases diffi cult to treat, with 
high disease activity or long-standing disease. Compatible with 
this possibility, patients who had been treated with three or 
more non-biological DMARD before enrolment in REAL had a 
signifi cantly longer disease duration with more advanced dis-
ease stages and classes than those receiving less than three non-
biological DMARD (data not shown). It has been reported that 
advanced stage or higher disease activity was reported as a risk 
for infections.8 29 50
Our study has limitations. First, we have to mention the pos-
sibility of selection bias in this study. However, because almost 
all patients who were registered from the participating hospi-
tals of our study to the all-cases postmarketing surveillance pro-
grammes for each biological DMARD were enrolled in REAL, 
selection bias was substantially decreased. Second, we analy-
sed the fi rst biological agent administered to each patient at or 
after enrolment in REAL. However, these biological agents were 
not necessarily truly the fi rst one used for each patient; rates 
of biological-naive patients were signifi cantly different among 
the three groups (table 1), indicating the presence of channelling 
bias. Therefore, we adjusted for the previous use of biological 
agents in the multivariate analysis.
In conclusion, we have presented the fi rst epidemiological 
data that directly compare TNF inhibitors and tocilizumab in 
a single cohort. We demonstrated that reasons for discontinua-
tion were signifi cantly different among the biological agents and 
that the use of infl iximab and tocilizumab had a signifi cantly 
higher risk of treatment discontinuation due to AE compared 
with etanercept after adjusting for various confounding factors.
Values are the mean±SD, unless otherwise stated. For 
univariate analysis, the χ2 test for categorical variables and the 
Student’s t test or Mann–Whitney test were used to compare 
continuous variables among groups.
Steinbrocker’s classifi cation30 was used to defi nite RA disease 
stages and classes.
The immunosuppressive drugs used were tacrolimus, lefl uno-
mide, mizoribine and ciclosporin.
Table 3 Multivariate analysis for drug discontinuation due to adverse events in RA patients treated with 
infl iximab, etanercept or tocilizumab*
 HR (95% CI) p Value
Infl iximab (vs etanercept) 1.69 (1.14 to 2.51) 0.009
Tocilizumab (vs etanercept) 1.98 (1.04 to 3.76) 0.037
Age by decade 1.64 (1.38 to 1.97) <0.001
Class 3 or 4 (vs class 1 or 2) 1.07 (0.74 to 1.54) 0.727
DAS28 (3/CRP) at baseline (per 1.0 increment) 1.03 (0.92 to 1.17) 0.585
Chronic pulmonary disease 1.19 (0.83 to 1.70) 0.336
Diabetes mellitus 0.95 (0.58 to 1.56) 0.841
Concomitant use of oral corticosteroids at baseline 1.15 (0.78 to 1.70) 0.489
Concomitant use of immunosuppressive drugs except for methotrexate at baseline 0.56 (0.20 to 1.55) 0.262
Previous use of three or more non-biological DMARD 1.86 (1.30 to 2.67) 0.001
Previous use of biological agents 1.05 (0.64 to 1.72) 0.842
*Cox regression hazard model analysis, adjusted for the variables included in the table, gender and calendar year.
Class, Steinbrocker’s class; CRP, C-reactive protein; 
DAS28, disease activity score including 28-joint count; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.
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The oral corticosteroid dose was converted to the equivalent 
prednisolone dosage. Methotrexate and corticosteroid doses are 
shown as the mean±SD among users of these drugs.
Chronic pulmonary diseases include interstitial pneumonia, 
chronic obstructive pulmonary disease, bronchial asthma, previ-
ous pulmonary tuberculosis and bronchiectasis.
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